Literature DB >> 12175482

Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats.

Irene Massari1, Alessia Donnini, Katy Argentati, Stefania Straino, Antonella Mangoni, Carlo Gaetano, Claudio Viticchi, Maurizio Capogrossi, Mauro Provinciali.   

Abstract

We evaluated the kinetics of transgene expression and humoral and cellular immune responses against viral antigens and the product of the reporter gene LacZ in young (4 months) and old (20 months) Wistar rats. Animals received the intramuscular injection of a recombinant E1-deleted human type 5 adenovirus encoding beta-gal (Ad-LacZ) on days 0 and 30. The transgene expression evaluated on day 2 after infection revealed a significantly higher beta-gal activity in young than in old animals (1.9-fold increase, p<0.05). beta-gal expression decreased on day 6, and on day 15 transgene activity was undetectable in muscles from both groups. Ad-LacZ inoculation was repeated on day 30 in both animal groups. However, after the second adenovirus administration, no increase in beta-gal activity was observed. Humoral and cellular immune responses, evaluated after the first and second Ad-LacZ injection, developed with similar kinetics in young and old rats. In particular, the antigen specific antibodies were able to kill adenovirus-infected tumor cells in both complement-dependent cytotoxicity (CDC) and antibody-mediated cell-dependent cytotoxicity (ADCC) assays. Lymphocyte proliferation in response to the in vitro stimulation with specific antigens was significantly lower in old than in young animals whereas no difference was found in cytotoxic T lymphocyte activity against adenovirus-infected tumor cells. Our results demonstrate that repeated immunization with AdCMV.LacZ induces minor age-related differences in immune response which precludes gene expression both in young and old animals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12175482     DOI: 10.1016/s0531-5565(02)00011-6

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  8 in total

Review 1.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

2.  Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: application to nonstructural protein 1 in a model of Japanese encephalitis virus.

Authors:  Eiji Konishi; Yoko Kitai; Takashi Kondo
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

Review 3.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

Review 4.  Oncolytic viruses for cancer immunotherapy.

Authors:  Otto Hemminki; João Manuel Dos Santos; Akseli Hemminki
Journal:  J Hematol Oncol       Date:  2020-06-29       Impact factor: 17.388

Review 5.  Oncolytic viruses in cancer therapy.

Authors:  Markus J V Vähä-Koskela; Jari E Heikkilä; Ari E Hinkkanen
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

6.  Trial watch: Oncolytic viruses for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-04-16       Impact factor: 8.110

Review 7.  Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.

Authors:  Andrew Nguyen; Louisa Ho; Yonghong Wan
Journal:  Front Oncol       Date:  2014-06-11       Impact factor: 6.244

Review 8.  Trial Watch:: Oncolytic viruses for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Philippe Erbs; Jean-Marc Limacher; Xavier Preville; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-01       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.